Millennium Management
SKYE icon

Millennium Management’s Skye Bioscience SKYE Stock Holding History

Millennium Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,313
Closed -$167K – 6554
2025
Q3 		$167K Buy
+5,313
New +$161K ﹤0.01% 5593

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management's SKYE Position: Q2 2026 in Review

Millennium Management reduced its Skye Bioscience (SKYE) stake by 23% in Q2 2026, selling an estimated $46.9K and leaving 24,816 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #5417.

Millennium Management first reported a position in SKYE in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.97M in Q2 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Millennium Management held 24,816 shares of Skye Bioscience worth $138K as of Q2 2026.
  • Millennium Management sold 7,459 Skye Bioscience shares in Q2 2026, an estimated $46.9K.
  • Skye Bioscience made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #5417 holding.
  • Millennium Management first reported a position in Skye Bioscience in Q3 2024 and has held it in 6 quarters since.
  • Millennium Management's Skye Bioscience position peaked at $1.97M in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.